Science · Open for opinions
Will CRISPR Therapeutics initiate Phase 2 clinical trials for the CTX310 therapy by November 30, 2026?
Considers regulatory filings and clinical advancements announced between 10/01 and 11/30/2026. 74 opinions, 65% No
- Yes — 35%
- No — 65%
Deadline: November 30, 2026 at 11:59 PM UTC · 74 opinions
Resolution rules
Considers regulatory filings and clinical advancements announced between 10/01 and 11/30/2026.
Source: www.sciencedaily.com
Frequently asked questions about this event
How is this event resolved?
Janela de apuração: de 01/10/2026 (00:00, horário de Brasília) até 30/11/2026 (23:59). Fatos, anúncios ou eventos anteriores ao início da janela não contam. Resolve como 'Sim' se a CRISPR Therapeutics AG ou a plataforma ClinicalTrials.gov confirmar o avanço ou início de ensaios clínicos de Fase 2 para a terapia CTX310 até 30/11/2026, por meio de comunicado oficial ao mercado ou registro regulatório. Caso contrário, resolve como 'Não'.
How are points scored?
Points depend on the share of votes your side had when you gave your opinion. Being right earns 100 minus that share. Being wrong costs that share.
Right now No has 65% of the votes: an opinion on it that turns out right earns about 35 points, a wrong one costs about 65.